招商公路(001965.SZ)上半年扣非归母净利增13.97%至22.58亿元
格隆汇8月28日丨招商公路(001965.SZ)公布2019上半年业绩,公司实现营业收入36.88亿元,同比增长35.18%;归属于上市公司股东的净利润23.01亿元,同比增长14.38%;归属于上市公司股东的扣除非经常性损 益的净利润22.58亿元,同比增长13.97%。
2019年上半年,面对行业政策的变化以及充满挑战的市场环境,公司在董事会的统筹部署下,牢牢把握高质量发展根本要求和稳中求进工作总基调,围绕建设“中国领先、世界一流”公路企业战略目标,以科技创新为引领,以质效提升为抓手,以协同发展为保障,探索新模式、打造新动能,持续推动企业转型升级,经营业绩稳健增长。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.